- Previous Close
38.70 - Open
38.30 - Bid 39.00 x --
- Ask 39.40 x --
- Day's Range
38.30 - 39.40 - 52 Week Range
27.05 - 47.80 - Volume
68,118 - Avg. Volume
202,927 - Market Cap (intraday)
1.803B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
151.54 - EPS (TTM)
0.26 - Earnings Date --
- Forward Dividend & Yield 0.50 (1.27%)
- Ex-Dividend Date Aug 27, 2024
- 1y Target Est
--
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese medicine products, such as pills for liver and kidney deficiency, low back pain, sore feet, dizziness, thirst, dry tongue, sore throat, and heel pain, as well as rheumatism, joint pain, traveling pain, wind-cold-dampness, gout, neuralgia, enuresis, hemorrhoids, constipation, athlete's foot, fall injuries, cold, bronchitis, cough, and phlegm indications. It provides western medicine products, including ointment, hair removal cream, tablet, capsule, soreness spray, and pain patch products, as well as pain relief gels. In addition, the company offers healthcare products; and other products for body relaxation and comfort, and relieving discomfort after exercise, as well as tooth products and soaps. The company was founded in 1960 and is based in New Taipei City, Taiwan.
www.tlb.com.tw61
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 4127.TWO
View MorePerformance Overview: 4127.TWO
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4127.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4127.TWO
View MoreValuation Measures
Market Cap
1.80B
Enterprise Value
2.02B
Trailing P/E
151.54
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.68
Price/Book (mrq)
3.77
Enterprise Value/Revenue
5.24
Enterprise Value/EBITDA
79.14
Financial Highlights
Profitability and Income Statement
Profit Margin
3.04%
Return on Assets (ttm)
0.05%
Return on Equity (ttm)
2.41%
Revenue (ttm)
385.21M
Net Income Avi to Common (ttm)
11.7M
Diluted EPS (ttm)
0.26
Balance Sheet and Cash Flow
Total Cash (mrq)
130.67M
Total Debt/Equity (mrq)
70.17%
Levered Free Cash Flow (ttm)
52.22M